Drug-induced arterial hypertension

This review is devoted to the problem of drug-induced hypertension (H). It summarizes the literature data on drugs and substances that can increase blood pressure, discusses the mechanisms of their hypertensive action. Many classes of drugs such as steroids, nonsteroidal anti-inflammatory drugs, sympathomimetics, immunosuppressants, oral contraceptives, antidepressants, erythropoietin, etc. can cause episodic or persistent increase in blood pressure, cause uncontrolled hypertension, reduce the effectiveness of antihypertensive drugs. The development of drug-induced hypertension is realized through a number of pathophysiological mechanisms: sodium retention with subsequent increase in the volume of circulating blood, activation of the sympathetic nervous system, direct effect on the smooth muscles of arterioles, there are other, not fully studied mechanisms. Drug-induced H may also be the result of pharmacokinetic or pharmacodynamic drug interactions. To suspect the presence of drug-induced hypertension, in the first place, should be in persons with newly diagnosed hypertension, as well as in patients who previously had a well-controlled hypertension (stable target blood pressure - BP levels) when they have episodes of unexplained increase in BP without a clear relationship with physical or psycho-emotional stress. It is very important to have a properly collected history with a focus on a thorough assessment of the medicines taken by the patient, especially newly prescribed, as well as those purchased at the pharmacy independently, including over-the-counter, this will avoid unnecessary and/or expensive studies and unnecessary prescriptions of additional antihypertensive drugs. The article presents these measures for the prevention and correction of drug-induced H. The appointment of new drugs by a doctor to patients receiving antihypertensive therapy should necessarily take into account their impact on the risk of drug-induced hypertension. Prescribing drugs that cause an increase in BP levels should either be avoided or, if alternative treatment regimens are not possible, strict control of the patient's BP level (including the method of home monitoring of BP) and, if necessary, the correction of antihypertensive therapy. When canceling a drug that causes drug-induced hypertension, BP returns to its original level, which is proof of the iatrogenic cause of hypertension.

arterial hypertension, drug-induced hypertension, secondary arterial hypertension, drugs

1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339

2. Diaconu C.C, Dediu G.N, Lancu M.A. Drug-induced arterial hypertension - a frequently ignored cause of secondary hypertension: a review. Acta Cardiol 2018; 1: 1-7. DOI: 10.1080/00015385.2017.1421445

3. Gyamlani G, Geraci S.A. Secondary Hypertension due to Drugs and Toxins. South Med J 2007; 100 (7): 692-9; quiz 700, 708. DOI: 10.1097/SMJ.0b013e318063c3e8

4. Page B, Amoura Z, Grunfeld J.P. Effects of corticosteroids on bone and blood pressure. Contrib Nephrol 1992; 99: 60-5.

5. Kaplan N.M. Hypertension induced by cortisol or deoxycorticosterone. In Kaplan NM (ed): Clinical Hypertension, 6th edn. Baltimore: Williams & Wilkins, 1994; pp 343-65.

6. Whitworth J.A. Mechanisms of glucocorticoid-induced hypertension. Kidney Int 1987; 31: 1213-24.

7. Whitworth J.A, Brown M.A, Kelly J.J, Williamson PM. Mechanisms of cortisol-induced hypertension in humans. Steroids 1995; 60 (1): 76-80.

8. Pirpiris M, Sudhir K, Yeung S et al. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19 (6 Pt 1): 567-74.

9. Клиническая фармакология и фармакотерапия: учеб. для студентов медицинских вузов. Под ред. В.Г.Кукеса, А.К.Стародубцева. М.: ГЭОТАР-Медиа, 2012.

10. Brem A.S. Insights into glucocorticoid-associated hypertension. Am J Kidney Dis 2001; 37: 1-10.

11. Ulick S, Levine L.S, Gunczler P et al. A syndrome of apparent mineralcorticoid exess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49 (5): 757-64. DOI: 10.1210/jcem-49-5-757

12. Aabo K, De coster R. Hypertension during high-dose ketoconazole treatment: a probable mineralcorticosteroid effect. Lancet 1987; 2: 637-38.

13. Weir R.J. Effect on blood pressure of changing from high to low dose steroid preparations in women with oral contraceptive induced hypertension. Scott Med J 1982; 27: 212-5. DOI: 10.1177/003693308202700303

14. Royal College of General Practitioners Oral Contraceptive Study. Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 1977; 1: 624.

15. Khaw K, Peart W.S. Blood pressure and contraceptive use. Br Med J 1982; 285: 402-7.

16. Spellacy W.N, Birk S.A. The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens on blood pressure. Am J Obstet Gynecol 1972; 112: 912-19.

17. Mandel F.P, Geola F.L, Lu J.K et al. Biologic effects of various doses of ethynil estradiol in postmenopausal women. Obster Gynecol 1982; 59: 673-679.

18. Report of the Royal College of General Practitioners. Hypertension. In: Oral contraceptives and health. London: Pitmann, 1974; p. 37-42.

19. Шмелева Е.В., Зиганшина Л.Е., Салихов И.Г. Побочные эффекты гормональных контрацептивов. Казанский мед. журн. 2006; 5: 366-9.

20. Bretza J.A, Novey H.S, Vaziri N.D, Warner A.S. Hypertension: a complication of danazol therapy. Arch Intern Med 1980; 140: 1379-80.

21. Rübig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climateric 2003; 6 (Suppl. 3): 49-54.

22. Krattenmaccher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38.

23. Nisenbaum M.G, Melo N.R, Giribela C.R et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62-6. DOI: 10.1016/j.ejogrb.2014.01.006

24. Preston R.A, Alonso A, Panzitta D. Additive effect of drospirenone/17-BETA-estradiol in hypertensive postmenopausal women receiving Enalapril. Am J Hypertens 2002; 15: 816-22.

25. Preston R.A, White W.B, Pitt B. Effects of drospirenone/17-b estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005; 18 (6): 797-804. DOI: 10.1016/j.amjhyper.2004.12.003

26. White W.B, Pitt B, Preston R.A, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal woman with stage 1 hypertension. Circulation 2005; 112: 1979-1980. DOI: 10.1161/CIRCULATIONAHA.104.501502

27. de Morais T.L, Giribela C, Nisenbaum M.G et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. Eur J Obstet Gynecol Reprod Biol 2014; 182: 113-7. DOI: 10.1016/j.ejogrb.2014.09.006

28. Серов В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология: учебник для студентов медицинских вузов. М.: МЕДпресс-информ, 2004; с. 391-2.

29. Кулаков В.И., Кулаков В.И., Сметник В.П. Руководство по климактерию. М.: Медицинское информационное агентство, 2001; с. 404-95.

30. Барт Б.Я., Бороненков Г.М., Беневская В.Ф. Артериальная гипертония у женщин в постменопаузе: современные возможности медикаментозной терапии в поликлинических условиях. Рос. кардиол. журн. 2001; 5: 69-70. [Bart B.Ia., Boronenkov G.M., Benevskaia V.F. Arterial'naia gipertoniia u zhenshchin v postmenopauze: sovremennye vozmozhnosti medikamentoznoi terapii v poliklinicheskikh usloviiakh. Ros. kardiol. zhurn. 2001; 5: 69-70 (in Russian).]

31. Курбанова З.К. Влияние низкодозированных комбинированных оральных контрацептивов на эндотелий сосудов. Архив акушерства и гинекологии им. В.Ф.Снегирева. 2015; 4: 46-7.

32. Cannon C, Curtis S, FitzGerald G et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthiritis Long-term programme. Lancet 2006; 18: 771-81. DOI: 10.1016/S0140-6736(06)69666-9

33. Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013; 2.

34. White W, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39 (4): 929-34.

35. Sowers J, White W, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165 (2): 161-8. DOI: 10.1001/archinte.165.2.161

36. Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens 2011; 2011: 236-9. DOI: 10.4061/2011/236239

37. Weber M.A. Treatment of patients with hypertension and arthritis pain: new concepts. Am J Med 2009; 122 (Suppl. 5): S16-22. DOI: 10.1016/j.amjmed.2009.03.004

38. Johson A.G, Nguyen T.V, Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300.

39. Лазебник Л.Б., Коцюбинская О.Б., Конев О.В., Дроздов В.Н. Влияние нестероидных противовоспалительных препаратов и трамала на уровень артериального давления при лечении остеоартроза у больных с артериальной гипертонией. Научно-практическая ревматология. 2004; 1: 28-33. DOI: 10.14412/1995-4484-2004-1

40. Varas Lorenzo C, Riero-Guardia N, Calingaert B et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225-36. DOI: 10.1002/pds.2227

41. Fanelli A, Ghisi D, Aprile P.L, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. Ther Adv Drug Saf 2017; 8 (6): 173-82. DOI: 10.1177/2042098617690485

42. Еlliot M. Antman AHA Scientific Statements Use of Nosteroidal Antiflammotory Drugs. Circulation 2007; 115 (12): 1634-42. DOI: 10.1161/CIRCULATIONAHA.106.181424

43. Houston M.C. Nonsteroidal anti-inflammatory drugs and antihypertensives. Am J Med 1991; 90 (5A): 42S-47S.

44. Wong D.G, Spence J.D, Lamki L et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1: 997-1001.

45. White W.B, Faich G, Whelton A et al. Comparison of thromboembolic events in patients treated with celecoxib, a cuclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002; 89: 425-30.

46. Moore N, Salvo F, Duong M et al. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Exp Opin Drug Saf 2014; 13 (2): 167-79. DOI: 10.1517/14740338.2014.846324

47. Houston M.C, Weir M, Gray J et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155 (10): 1049-54.

48. Moore R.A, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007; 8: 73. DOI: 10.1186/1471-2474-8-73

49. Furey S.A, Vargas R, McMahon F.G. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13 (2): 143-8.

50. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и др. Результаты фармакоэпидемиологического исследования артериальной гипертонии Пифагор IV: приверженность врачей. Рос. кардиол. журн. 2015; 1 (117): 59-66. doi.org/10.15829/1560-4071-2015-1-59-66.

51. Stollberger C, Findterer J. Side effects of conventional nonsteroidal anti-inflammatory drugs and celecoxib: more similarities than differences. South Med J 2004; 97 (2): 209-19. doi: 10.1097/01.SMJ.0000093569.26036.27

52. Combe B, Landewe R, Daien C.I. 2016 update of the Europian League Against Rheumatism recommendations for the management of early arthritis. Ann Rheum Dis 2017; 76 (6): 948-59. DOI: 10.1136/annrheumdis-2016-210602

53. Hochberg M.C, Altman R.D, April K.T et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012; 64 (4): 465-74.

54. Amsterdam J.D, Garcia Espana F, Fawcett J et al. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19 (1): 9-14.

55. Kaufmann J.S. Letter: Pheochromocytoma and tricyclic antidepressants. JAMA 1974; 229 (10): 1282.

56. Loule A.K, Louie E.K, Lannon R.A. Systemic hypertension associated with tricyclic antidepressant treatment in patients with panic disorder. Am J Cardilol 1992; 70 (15): 1306-9.

57. Thase M.E. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59 (10): 502-8.

58. Roche H, Hyman G, Nahas G. Hypertension and Intravenous antidopaminergic drugs. N Engl J Med 1985; 312 (17): 1125-6.

59. Sheridan C, Chandra P, Jacinto M et al. Transient hypertension after high doses of metoclopramide. N Engl J Med 1982; 307 (21): 1346. DOI: 10.1056/NEJM198211183072118

60. Barjon P, Fourcade J, Mimran A, Charra B. Paroxysmal hypertension during L-dopa treatment in parkinsonism: a metabolic error or a pharmacological effect? Rev Eur Etud Clin Biol 1972; 17 (2): 187-192.

61. Cain J.W. Hypertension associated with oral administration of physostigmine in a patient with Alzheimer’s disease. Am J Psychiatry 1986; 143 (7): 910-2. DOI: 10.1176/ajp.143.7.910

62. Scott D.L, Smolen J.D, Kalden J.R et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60 (10): 913-23.

63. Akpunonu B.E, Mulrow P.J, Hoffman E.A. Secondary hypertension: evaluation and treatment: thyrotoxicosis and hypertension. Dis Mon 1996; 42 (10): 689-702.

64. Liu L.X, Rustgi A.K. Cardiac myonecrosis in hypertensive crisis associated with monoamine oxidase inhibitor therapy. Am J Med 1987; 82 (5): 1060-4.

65. Robert N, Wong G.W, Wright J.M. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; 1: CD007893. DOI: 10.1002/14651858

66. Cush J.J, Tugwell P, Weinblatt M, Yocum D. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26 (5): 1176-86.

67. Artz M.A, Boots J.M, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-oflife indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4 (6): 937-45. DOI: 10.1111/j.1600-6143.2004.00427.x

68. Ranpura V, Pulipati B, Chu D et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23 (5): 460-8. DOI: 10.1038/ajh.2010.25

69. Wu S, Chen J.J, Kudelka A et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 2008; 9 (2): 117-23. DOI: 10.1016/S1470-2045(08)70003-2

70. Rini B.I, Schiller J.H, Fruehauf J.P et al. Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011; 17 (11): 3841-9. DOI: 10.1158/1078-0432.CCR-10-2806

71. Laragh J.H. Renin-Guided Therapy. Clinical Hypertension Review Course Syllabus. Am Soc Hypertens 2005; 353-355.

72. Diaconu C, Nastasa A, Abdul Rehman Z et al. A comparative analysis of the hypertension treatment depending on comorbidities: insights from clinical practice. J Hypertens 2016; 34 (e-Suppl. 1): e320. DOI: 10.1097/01.hjh.0000492280.96930.f6

73. Diaconu C, Istratie B, Nastasa A et al. An age-related comparison between comorbidities and treatment of hypertensive patients. J Hypertens 2016; 34 (e-Suppl. 1): e321. DOI: 10.1097/01.hjh.0000492283.81683.1a.

74. Lowenstein E. Sympathetic nervous system activation and hyperdynamic circulation associated with desflurane: not all isomers are created equal. Anesthesiology 1993; 79 (3): 419-21.

75. Amaranath L, Zanettin G.G, Bravo E.L et al. Atracurium and pheochromocytoma: a report of three cases. Anesth Analg 1988; 67 (11): 1127-30.

76. Joyce D.A, Gubbay S.S. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. Br Med J (Clin Res Ed) 1982; 285 (6337): 260-1.

77. Taylor G.J. Cohen Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet Gynecol 1985; 66 (6): 821-2.

78. Bakht F.R, Kirshon B, Baker T, Cotton D.B. Postpartum cardiovascular complications after bromocriptine and cocaine use. Am J Obstet Gynecol 1990; 162 (4): 1065-6.

79. Watson D.L, Bhatia R., Norman G.S et al. Bromocriptine mesylate for lactation suppression: a risk for postpartum hypertension? Obstet Gynecol 1989; 74 (4): 573-6.

80. Gorun G.S, Dermengiu D, Curca G.C et al. Toxicological drivers issues in “legal highs” use. Rom J Leg Med 2010; XVIII (4): 271-9. DOI: 10.4323/rjlm.2010.271

81. Izzo A.A, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98 (1): 1-14. DOI: 10.1016/j.ijcard.2003.06.039

82. Abhyankar L.N, Jones M.R, Guallar E, Navas-Acien A. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012; 120 (4): 494-500. DOI: 10.1289/ehp.1103988

83. Sofer S, Shalev H, Weizman Z et al. Acute pancreatitis in children following envenomation by the yellow scorpion Leiurus quinquestriatus. Toxicon 1991; 29 (1): 125-8.

84. Saadeh A.M, Farsakh N.A, al-Ali M.K. Cardiac manifestations of acute carbamate and organophosphate poisoning. Heart 1997; 77 (5) :461-4.

85. World Hypertension League: Nonpharmacological interventions as an adjunct to the pharmacological treatment of hypertension. J Hum Hypertens 1993; 7 (2): 159-64.

86. Grossman E, Messerli F.H. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125 (1): 14-22. DOI: 10.1016/j.amjmed.2011.05.02

87. Lancu M.A, Diaconu C, Dediu G et al. An analysis of hypertensive male patients addresses to a primary practice. J Hypertens 2016; 34 (e-Supplement 2): e323. DOI: 10.1097/01.hjh.0000492291.09500.3a